Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Rigel Pharmaceuticals Financial Conference Call for the fourth quarter and full year 2025. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Fury, Riesel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you, Mr. Fury. You may begin. Welcome to our fourth quarter and full year 2025 financial results and business update conference call. The financial press release for the fourth quarter and the full year 2025 was issued a short while ago can be viewed along with the slides for this presentation in the news and events section of our investor relations site on risal.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on forward on Form 10-K for the year ended December 31st, 2025, on file with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances. At this time, I'd like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul. Thank you, Ray, and thank you all for joining us today. Also with me are Dave Santos, our Chief Commercial Off...